Agonist-Independent Interactions between β-Arrestins and Mutant Vasopressin Type II Receptors Associated with Nephrogenic Syndrome of Inappropriate Antidiuresis

Molecular Endocrinology

Volumn 23, Issue 4, 2009, Pages 559-571

  Kocan, Martina ^a   See, Heng B ^a   Sampaio, Natália G ^a   Eidne, Karin A ^a   Feldman, Brian J ^b   Pfleger, Kevin D G ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; HYBRID PROTEIN; VASOPRESSIN V2 RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; INAPPROPRIATE VASOPRESSIN SECRETION; MISSENSE MUTATION; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; ARGININE VASOPRESSIN; ARRESTINS; CELL LINE; DIABETES INSIPIDUS, NEPHROGENIC; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; INFANT; MALE; MICROSCOPY, CONFOCAL; RECEPTORS, VASOPRESSIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 64749087041     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2008-0321     Document Type: Article

References (39)

1. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda- Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE 2005 Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352:1884-1890
2. Bes DF, Mendilaharzu H, Fenwick RG, Arrizurieta E 2007 Hyponatremia resulting from arginine vasopressin receptor 2 gene mutation. Pediatr Nephrol 22:463-466
3. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C 2007 Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 18:606-612
4. Marcialis MA, Faa V, Fanos V, Puddu M, Pintus MC, Cao A, Rosatelli MC 2008 Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol 23:2267-2271
5. Soule S,Florkowski C, Potter H, PattisonD, Swan M, Hunt P, George P 2008 Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Ann Clin Biochem 45:520-523
6. Zerbe R, Stropes L, Robertson G 1980 Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 31:315-327
7. Rosenthal SM, Gitelman SE, Vargas GA, Feldman BJ 2007 Gain-of-function mutations in the V2 vasopressin receptor. Horm Res 67:121-125
8. Gitelman SE, Feldman BJ, Rosenthal SM 2006 Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am J Med 119:S54-S58
9. Robertson GL 2001 Antidiuretic hormone: normal and disordered function. Endocrinol Metab Clin North Am 30:671-694
10. Verbalis JG 2003 Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 17:471-503
11. Schrier RW, Cadnapaphornchai MA 2003 Renal aquaporin water channels: from molecules to human disease. Prog Biophys Mol Biol 81:117-131
12. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG 1999 Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 274:32248-32257
13. Dromey JR, Pfleger KD 2008 G protein coupled receptors as drug targets: the role of β-arrestins. Endocr Metab Immune Disord Drug Targets 8:51-61
14. Charest PG, Oligny-Longpré G, Bonin H, Azzi M, Bouvier M 2007 The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal 19:32-41
15. Filipek S, Stenkamp RE, Teller DC, Palczewski K 2003 G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol 65:851-879
16. Rovati GE, Capra V, Neubig RR 2007 The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959-964
17. Birnbaumer M 1995 Mutations and diseases of G protein coupled receptors. J Recept Signal Transduct Res 15:131-160
18. Bichet DG 1998 Nephrogenic diabetes insipidus. Am J Med 105:431-442
19. Rosenthal W, Antaramian A, Gilbert S, Birnbaumer M 1993 Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem 268:13030-13033
20. Barak LS, Oakley RH, Laporte SA, Caron MG 2001 Constitutive arrestinmediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 98:93-98
21. Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG, Bouvier M 2004 Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 18:2074-2084
22. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperrière A, Brouard R, Bouvier M, Bichet DG 2006 Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 17:232-243
23. Wu P, Brand L 1994 Resonance energy transfer: methods and applications. Anal Biochem 218:1-13
24. Pfleger KD, EidneKA 2006 Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 3:165- 174
25. Pfleger KD, Seeber RM, Eidne KA 2006 Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat Protoc 1:337-345
26. Pfleger KD, Dromey JR, Dalrymple MB, Lim EM, Thomas WG, Eidne KA 2006 Extended bioluminescence resonance energy transfer (eBRET) for monitoring prolonged protein-protein interactions in live cells. Cell Signal 18:1664-1670
27. KocanM, See HB, Seeber RM, EidneKA, Pfleger KD 2008 Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J Biomol Screen 13:888-898
28. Morin D, Cotte N, Balestre MN, Mouillac B, Manning M, Breton C, Barberis C 1998 The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett 441:470-475
29. Damke H, Baba T, Warnock, DE, Schmid SL 1994 Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 127:915-934
30. Pfleger KD, Dalrymple MB, Dromey JR, Eidne KA 2007 Monitoring interactions between G-protein-coupled receptors and β-arrestins. Biochem Soc Trans 35:764-766
31. Miserey-Lenkei S, Parnot C,Bardin S, Corvol P, Clauser E 2002 Constitutive internalization of constitutively active angiotensin IIAT1A receptor mutants is blocked by inverse agonists. J Biol Chem 277:5891-5901
32. Innamorati G, Sadeghi HM, Tran NT, Birnbaumer M 1998 A serine cluster prevents recycling of the V2 vasopressin receptor. Proc Natl Acad Sci USA 95:2222-2226
33. Bouley R, Lin HY, Raychowdhury MK, Marshansky V, Brown D, Ausiello DA 2005 Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway. Am J Physiol Cell Physiol 288:C1390-C1401
34. Loening AM, Fenn TD, Wu AM, Gambhir SS 2006 Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel 19:391-400
35. He L, Simmen FA, Mehendale HM, Ronis MJ, Badger TM 2006 Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J Biol Chem 281:11126-11134
36. Wang L, Shao J, Muhlenkamp P, Liu S, Klepcyk P, Ren J, Friedman JE 2000 Increased insulin receptor substrate-1 and enhanced skeletal muscle insulin sensitivity in mice lacking CCAAT/enhancer-binding protein β. J Biol Chem 275:14173-14181
37. Arizmendi C, Liu S, Croniger C, Poli V, Friedman JE 1999 The transcription factor CCAAT/enhancer-binding protein β regulates gluconeogenesis and phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J Biol Chem 274:13033-13040
38. Schroeder-Gloeckler JM, Rahman SM, Janssen RC, Qiao L, Shao J, Roper M, Fischer SJ, Lowe E, Orlicky DJ, McManaman JL, Palmer C, Gitomer WL, Huang W, O'Doherty RM, Becker TC, Klemm DJ, JensenDR, Pulawa LK, Eckel RH, Friedman JE 2007 CCAAT/enhancer-binding protein /3 deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. J Biol Chem 282:15717-15729
39. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J 2006 C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10:203-214